Generic placeholder image

Mini-Reviews in Medicinal Chemistry

Author(s): Beni B. Wolf, Clifford Quan, Thuy Tran, Christian Wiesmann and Daniel Sutherlin

DOI: 10.2174/138955708784567449

DownloadDownload PDF Flyer Cite As
On The Edge of Validation – Cancer Protease Fibroblast Activation Protein

Page: [719 - 727] Pages: 9

  • * (Excluding Mailing and Handling)

Abstract

Numerous studies implicate the prolyl peptidase, fibroblast activation protein (FAP) in tumorigenesis; however, FAP-selective inhibitors have not yet been developed to fully validate FAP as a therapeutic target. Herein, we review recent efforts aimed at validating and inhibiting FAP for cancer therapy and highlight future directions for successful targeting of this prolyl peptidase.

Keywords: FAP, DPP4, dipeptidyl peptidase, prolyl peptidase, inhibitor, cancer